Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials
Myeongju Cho, Tae Young Lee, Yoo Bin Kwak, et al.
Australian & New Zealand Journal of Psychiatry (2019) Vol. 53, Iss. 8, pp. 742-759
Open Access | Times Cited: 113

Showing 1-25 of 113 citing articles:

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Thomas R. E. Barnes, Richard Drake, Carol Paton, et al.
Journal of Psychopharmacology (2019) Vol. 34, Iss. 1, pp. 3-78
Open Access | Times Cited: 513
Cytokine Alterations in Schizophrenia: An Updated Review
Sara Momtazmanesh, Ameneh Zare-Shahabadi, Nima Rezaei
Frontiers in Psychiatry (2019) Vol. 10
Open Access | Times Cited: 225
The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress
Ganesh Raghu, Michael Berk, Peter A. Campochiaro, et al.
Current Neuropharmacology (2020) Vol. 19, Iss. 8, pp. 1202-1224
Open Access | Times Cited: 183
Mechanisms underlying dorsolateral prefrontal cortex contributions to cognitive dysfunction in schizophrenia
Jason Smucny, Samuel J. Dienel, David A. Lewis, et al.
Neuropsychopharmacology (2021) Vol. 47, Iss. 1, pp. 292-308
Open Access | Times Cited: 163
Schizophrenia and Inflammation Research: A Bibliometric Analysis
Heli Sun, Wei Bai, Xiaohong Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 115
Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia
Katsuhiko Hagi, Tadashi Nosaka, Dwight Dickinson, et al.
JAMA Psychiatry (2021) Vol. 78, Iss. 5, pp. 510-510
Open Access | Times Cited: 109
European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia
Antonio Vita, Wolfgang Gäebel, Armida Mucci, et al.
European Psychiatry (2022) Vol. 65, Iss. 1
Open Access | Times Cited: 88
The Role of Estrogen Receptors and Their Signaling across Psychiatric Disorders
Wu Jeong Hwang, Tae Young Lee, Nahrie Suk Kim, et al.
International Journal of Molecular Sciences (2020) Vol. 22, Iss. 1, pp. 373-373
Open Access | Times Cited: 129
The Role of Inflammation in the Treatment of Schizophrenia
Guillaume Fond, Christophe Lançon, Théo Korchia, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 113
Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders – A comprehensive systematic review and meta-analysis
Rose Jeppesen, Rune Haubo Bojesen Christensen, Emilie M.J. Pedersen, et al.
Brain Behavior and Immunity (2020) Vol. 90, pp. 364-380
Closed Access | Times Cited: 99
Neuroinflammation in schizophrenia: the role of nuclear factor kappa B
Caitlin E. Murphy, Adam K. Walker, Cynthia Shannon Weickert
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 84
Abnormal synaptic pruning during adolescence underlying the development of psychotic disorders
M. Germann, Sanne Brederoo, Iris E. Sommer
Current Opinion in Psychiatry (2021) Vol. 34, Iss. 3, pp. 222-227
Open Access | Times Cited: 71
Taurine, an essential β-amino acid insulates against ketamine-induced experimental psychosis by enhancement of cholinergic neurotransmission, inhibition of oxidative/nitrergic imbalances, and suppression of COX-2/iNOS immunoreactions in mice
Benneth Ben‐Azu, Olusegun G. Adebayo, Theophilus Aghogho Jarikre, et al.
Metabolic Brain Disease (2022) Vol. 37, Iss. 8, pp. 2807-2826
Closed Access | Times Cited: 43
MicroRNA schizophrenia: Etiology, biomarkers and therapeutic targets
Heng-Chang Zhang, Yang Du, Lei Chen, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 146, pp. 105064-105064
Closed Access | Times Cited: 36
Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis
Bruna Panizzutti, David Skvarc, Sylvia Chu Lin, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5250-5250
Open Access | Times Cited: 32
Is It Time for a Paradigm Shift in the Treatment of Schizophrenia? The Use of Inflammation-Reducing and Neuroprotective Drugs—A Review
A. Messina, Carmen Concerto, Alessandro Rodolico, et al.
Brain Sciences (2023) Vol. 13, Iss. 6, pp. 957-957
Open Access | Times Cited: 24
Inflammatory cerebrospinal fluid markers in schizophrenia spectrum disorders: A systematic review and meta-analysis of 69 studies with 5710 participants
Nicola Warren, Cullen O’Gorman, Isabelle Horgan, et al.
Schizophrenia Research (2024) Vol. 266, pp. 24-31
Open Access | Times Cited: 15
Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Schizophrenia Bulletin Open (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 12
Clinical practice guidelines for assessment and management of cognitive impairment in schizophrenia
Sandeep Grover, Debadatta Mohapatra, Sridhar Vaitheswaran, et al.
Indian Journal of Psychiatry (2025) Vol. 67, Iss. 1, pp. 65-83
Open Access | Times Cited: 1
Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing
Jonghee Hong, Minji Bang
Clinical Psychopharmacology and Neuroscience (2020) Vol. 18, Iss. 1, pp. 10-24
Open Access | Times Cited: 69
Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
Monire Karbalaee, Melika Jameie, Mobina Amanollahi, et al.
Schizophrenia Research (2023) Vol. 254, pp. 92-98
Closed Access | Times Cited: 17
Conceptualization and characterization of “primary” and “secondary” cognitive impairment in schizophrenia
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Psychiatry Research (2024) Vol. 340, pp. 116126-116126
Open Access | Times Cited: 6
Neutrophil/lymphocyte, platelet/lymphocyte and monocyte/lymphocyte ratios in schizophrenia
Xiaoyu Zhu, Jia Zhou, Yu Zhu, et al.
Australasian Psychiatry (2021) Vol. 30, Iss. 1, pp. 95-99
Closed Access | Times Cited: 34
Cytokine Imbalance as a Biomarker of Treatment-Resistant Schizophrenia
N. А. Shnayder, Aiperi K. Khasanova, Anna Strelnik, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11324-11324
Open Access | Times Cited: 24
Side effects and cognitive benefits of buspirone: A systematic review and meta-analysis
Yue Du, Qing Li, Yikai Dou, et al.
Heliyon (2024) Vol. 10, Iss. 7, pp. e28918-e28918
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top